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CDK = cyclin dependent kinase; INK4 = inhibitor of CDK4; KIP = kinase inhibitor protein; Ubc = ubiquitin-conjugating enzyme.
Available online http://breast-cancer-research.com/content/3/2/091
Introduction
Cell cycle progression is governed by cyclin dependent
kinases (CDKs) that are activated by cyclin binding and
inhibited by CDK inhibitors [1]. CDKs regulate check-
points that integrate mitogenic and growth inhibitory
signals, coordinating cell cycle transitions. The passage
from G1 to S phase is regulated by the activities of cyclin
D1/CDK4, cyclin E/CDK2, and cyclin A/CDK2 complexes.
Cyclin B/CDK1 regulates the G2–M transition. Two fami-
lies of CDK inhibitors regulate the cell cycle. Members of
the inhibitor of CDK4 (INK4) family, such as p15INK4B and
p16INK4A, bind specifically to and inhibit CDK4 and CDK6.
In contrast, members of the kinase inhibitor protein (KIP)
family (p21CIP1, p27Kip1, and p57Kip2) have opposite
effects on the function of different CDKs. In fact, whereas
p27 and p21 have a negative effect on the activities of
cyclin E/CDK2 and cyclin A/CDK2, they seem to activate
cyclin D/CDK complexes. This is due to at least three dif-
ferent mechanisms: facilitation of the assembly of cyclin
D–CDKs complexes, increased nuclear localization of
these complexes, and increased stability of D type cyclins.
In proliferating cells p27 is prevalently bound to cyclin
D/CDKs, whereas in G1-arrested cells p27 is found in
complexes with cyclin E/CDK2. Therefore, the competition
for p27 between cyclin D/CDKs and cyclin E/CDK2 com-
plexes seems to be crucial for cell cycle progression,
because cyclin D/CDKs can sequester p27 from the
cyclin E/CDK2 complex and favor progression into S
phase [1].
Protein p27 was initially discovered in cells arrested by
transforming growth factor-a (TGF-a), by contact inhibi-
tion or by lovastatin [1]. Mitogenic factors cause loss of
p27, whereas p27 levels and/or activity increase in
response to differentiation signals, on loss of adhesion to
extracellular matrix and on signaling by growth inhibitory
factors such as TGF-a. Mice with p27 knockout develop
multiorgan hyperplasia and pituitary tumors, supporting a
Commentary
The cyclin dependent kinase inhibitor p27 and its prognostic role
in breast cancer
Roberto Chiarle*†, Michele Pagano* and Giorgio Inghirami*
*Department of Pathology, New York University School of Medicine, New York, New York, USA
†University of Torino, Torino, Italy
Correspondence: Giorgio Inghirami, Department of Pathology, New York University School of Medicine, New York, NY 10016, USA. 
Tel: +1 212 263 7768; fax: +1 212 263 7712; e-mail: inghig01@med.nyu.edu
Abstract
p27 is an inhibitor of cyclin dependent kinase involved in the regulation of the cell cycle. In this
commentary we discuss the current knowledge on p27 in breast cancer and its significance in
predicting the outcome. p27 protein levels are high in most cases of breast carcinomas, are correlated
with the levels of cyclin D1 and estrogen receptor, and could be a useful predictor of survival, because
they are low in aggressive carcinomas. Immunodetection of p27 in breast tumors could be useful in the
assessment of prognosis, especially in those cases in which the commonly used parameters are
insufficient, and might ultimately influence the therapy of this disease.
Keywords: breast cancer, cell cycle, p27, survival, ubiquitination
Received: 7 November 2000
Revisions requested: 17 November 2000
Revisions received: 28 November 2000
Accepted: 29 November 2000
Published: 20 December 2000
Breast Cancer Res 2001, 3:91–94
This article may contain supplementary data which can only be found
online at http://breast-cancer-research.com/content/3/2/091
© 2001 BioMed Central Ltd
(Print ISSN 1465-5411; Online ISSN 1465-542X)Breast Cancer Research    Vol 3 No 2 Chiarle et al
role for p27 in both proliferation and differentiation [1].
Furthermore, p27 haploinsufficient mice are more sensitive
to malignant tumor induction by radiation and chemical
carcinogens [2], and allelic haploinsufficiency for p27 is
found in some human tumors [3–5].
Whereas p27 mRNA levels are constant throughout the
cell cycle, p27 protein levels are high in quiescent cells
and decrease during G1 phase, reaching the lowest point
in S phase [6]. The decrease in p27 protein levels
observed in the passage from G1 to S phase is due to a
decrease in the p27 half-life, which in proliferating cells
becomes 6–8-fold shorter than in quiescent cells. This
shortening in half-life corresponds to an increased degra-
dation via the ubiquitin–proteasome pathway [7].
During ubiquitination and subsequent degradation, the
interaction between a ubiquitin-conjugating enzyme (Ubc)
and a substrate is mediated by the action of a ubiquitin
protein ligase. Ubiquitin ligases regulating the G1 phase
are called SCF complexes. The SCF ligases are each
formed by at least four basic subunits: Skp1, a Cullin
subunit (Cul1 in metazoans), an F-box protein, and the
Roc1/Rbx1 protein [8]. Each SCF ligase joins a Ubc
(Ubc3, Ubc4, or Ubc5) to specific substrates that are
recruited by different F-box proteins. Many F-box proteins
have been described for various substrates, and recent
results have demonstrated that Skp2 is the F-box protein
involved in p27 degradation. Indeed, cell cycle levels of
Skp2 are inversely correlated with p27 levels, with Skp2
expression low in early/mid-G1 and increasing in late G1,
in coordination with the decrease in p27 protein. Bio-
chemical and genetic experiments have demonstrated that
Skp2 is required for the ubiquitination and consequent
degradation of p27 both in vivo and in vitro [9–11].
Biological and prognostic implications of p27
levels in breast cancer
Most normal epithelial tissues, including breast, prostate,
lung, and ovary, express high levels of nuclear p27
protein, especially in the terminally differentiated layers. In
contrast, p27 is virtually undetectable in proliferating
cells, such as the basal layer of epithelia or lymphocytes
in germinal centers.
A variable loss of p27 protein has been shown in many
human tumors. Indeed, the loss of heterozygosity of the
12p13 locus encompassing the p27 gene is uncommon
in human tumors [3–5]. However, p27 gene biallelic
losses or mutations are very rarely found in breast carcino-
mas [12]. Thus, the decrease in p27 levels in some human
tumors has been related to an increased and deregulated
degradation. In fact, it has been shown that epithelial
cancers, lymphomas, and brain tumors display high and
often deregulated proteolytic activity of recombinant p27
protein in vitro [13–15].
In the last few years, interest has grown in understanding
the role and the implications of p27 levels in breast
cancers. The first three published studies tested the prog-
nostic value of p27 in breast tumors in comparison with
already well established parameters such as tumor stage,
grade, nodal status, hormone receptor levels, and S-phase
fraction. Porter et al [16] assayed both p27 and cyclin E
levels in 246 primary breast cancers of women under 45
years of age. Patients whose breast cancers showed both
low p27 and elevated cyclin E proteins had the highest
mortality, and multivariate analysis demonstrated that both
levels of p27 and cyclin E were independent predictors of
overall survival. Catzavelos et al [17] studied a cohort rep-
resentative of the breast cancer patient population. This
study found low staining of p27 in 56% of the tumors, and
loss of p27 was a strong independent predictor of
decreased disease-free survival, associated with a 2.7-fold
increased risk of disease relapse. Tumors with low p27
levels had higher cyclin E/CDK2 activities than those with
high p27 levels. Tan et al [18] examined the prognostic
value of p27 in 202 patients with breast cancers less than
1 cm in size (T1a,b) compared with clinicopathological
features and other parameters such as p53, c-erb-B2, Ki-
67, cdc25B, and the density of microvessels. This study
showed that low p27 levels, defined as fewer than 50% of
the tumor cells being positive for p27, were an indepen-
dent risk factor on multivariate analysis and were associ-
ated with a 3.4-fold increased risk of death, particularly in
node-negative tumors.
Subsequent studies on different groups of patients with
breast carcinoma have confirmed many of these first
observations. In fact, there is a general agreement that
high p27 levels are usually correlated with low histologic
grade, positive estrogen receptor status, high cyclin D1
expression, and low S-phase fraction [19–23]. Some
studies have also compared p27 protein levels and cyclin
E and/or cyclin D1 dependent kinase activities in breast
cancers, finding an inverse correlation between cyclin E
dependent kinase activity and p27 [24]. It has recently
also been shown that the treatment with 4D5 antibody of
the BT474 cell line derived from breast carcinoma
induced a shift of p27 from cyclin D/CDK4 to cyclin
E/CDK2 complexes and a consequent G1 arrest, suggest-
ing that the modulation of the levels and/or CDK binding
of p27 could be helpful in controlling the growth of breast
carcinoma cells [25]. However, the differences between
studies become evident when the relation between p27
and prognosis is analyzed in an attempt to establish the
importance of p27 as a single predictor of survival. Some
studies have shown p27 to be an independent variable in
multivariate analysis of survival [16–18]. Others proved
p27 to be a prognostic factor only in univariate analysis, as
compared with strong and well established prognostic
factors such as grade, size, nodal status, and S-phase
fraction [19,20,26]. Recently, two papers, one based on ac
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large group of consecutive breast carcinoma cases (512)
[22] and the other on 148 grade I breast carcinomas [23],
failed to find any prognostic relevance for p27 or cyclin
D1. The discrepancies resulting from all these studies
could be partly explained by considering the different anti-
bodies used for the immunohistochemical stainings or the
different criteria for p27 positivity used in the scoring
systems. In addition, p27 seems to be correlated with the
grading more than the staging, being less useful in a
homogeneous category such as grade I carcinomas [23].
Alternatively, it has to be considered that p27 is not the
only cell cycle inhibitor involved in breast carcinomas, an
almost equivalent role being established for p21 in con-
trolling the rate of cell cycle in cell lines derived from
breast tumors [27,28].
Finally, loss of p27 might precede tumor invasion but is
not related to particular subtypes of breast cancers.
Catzavelos  et al [17] observed a frequent loss of p27 in
non-invasive ductal breast carcinoma in situ. In both the in
situ and invasive components, lower p27 staining was
observed in high-grade tumors. Similar studies conducted
on less frequent subtypes of breast carcinomas, such as
infiltrating lobular or apocrine carcinoma, did not show sig-
nificant differences in p27 staining compared with the
more common infiltrating ductal carcinoma [29,30].
In conclusion, a loss of p27 seems to have prognostic
potential in breast tumors as for other types of tumor, such
as lymphomas and lung, colon, ovary, and prostate carci-
noma. This prognostic value could be especially useful in
tumors in which the classical survival parameters are insuf-
ficient, such as in small and nonmetastatic breast cancers.
This potential relies on the simplicity and reproducibility of
the immunohistochemical stainings for p27 as well as on
the growing number of studies on the deregulation of p27
function in human cancers. A better understanding of the
mechanisms regulating p27 expression and its interaction
with other oncogenes opens the possibility of selective
control of its degradation, raising the hope for the genera-
tion of new and more effective drugs for breast cancer.
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